Panacea-ml

Panacea-ml Overview

Spun out of Ben Gurion University, Panacea-ml is disrupting clinical development with its “Explainable AI” platform. We tackle the main causes of trial failures: patient population heterogeneity, poor trial design, and the limits of biostatistics. Together these problems are responsible for more than 85% of trial failures not related to drugs' mechanism of action, resulting in $70 billion annual waste and declining pharma R&D ROI. Panacea-ml's solution enables faster market access for new therapies with actionable predictive insights empowering clinical development and data science teams to de-risk, accelerate, and optimize trial designs. Our cutting-edge SaaS platform driven by our proprietary explainable AI is designed to redefine clinical development as our technology uncovers causal relationships between clinical markers, disease progression, and drug responses. Unlike traditional AI black-box models, Panacea-ml leverages causal discovery theory with its proprietary graphical models to not only predict clinical trials outcomes by to provide transparent, clinically-relevant insights into the ‘why’ behind the outcomes. This unique approach enhances predictive accuracy and enables actionable insights, improving trial success rates and R&D teams’ productivity. We validated our explainable-AI across 8 trials in areas like Diabetes, ALS, rare diseases, and oncology, where we enabled a 30% reduction in participants without compromising statistical power and a 60% increase in patient retention. Our platform also rescued a development program in diabetes after a failed Phase 3 trial. We target the $6B Data Analytics and Design segment of the $50B clinical trial market, focusing on high-failure areas like neurology and immuno-metabolic diseases. Panacea-ml aims to improve patients’ clinical outcomes, enhance their quality of life and accelerate access to life-treating therapies by redefining clinical development and empower pharma with advanced AI-analytic tools.

Cumulative Funding Raised Over Time ($)

Latest News

Jul 10, 2024 · www.einpresswire.com

growth-positive

PharmStars Announces the First Startup from Israel to Graduate from its Accelerator Program: Panacea-ml

Panacea-ml, an Israeli startup, has graduated from PharmStars, a pharma-focused accelerator for digital health startups. The company, which focuses on revolutionizing clinical trial design and clinical development decision-making with cutting-edge explainable AI, was part of the Spring 2024 cohort focused on Digital Innovations in Oncology. The graduation marks the successful completion of PharmStars 10-week educational and mentoring program, PharmaU. The program prepares startups to effectively engage with pharma companies as clients and partners.

Partners

Jul 2, 2024 · www.einpresswire.com

growth-positive

PharmStars Announces Spring 2024 Graduates: 10 Digital Health Startups Complete PharmStars’ Pharma-focused Accelerator

PharmStars, a pharma-focused accelerator for digital health startups, has announced the graduation of 10 startups from its Spring 2024 program. The program, which focused on Digital Innovations in Oncology, included a 10-week educational and mentoring program called PharmaU. The graduating startups, which were selected from applicants from 16 countries, each offer a unique digital health solution related to digital innovations in oncology. The startups presented their solutions to PharmStars’ pharma members at a Showcase Event in Boston, and participated in one-on-one meetings with them.

CustomersPartnersExpand

May 27, 2024 · www.mako.co.il

growth-positive

The program that will help startups in the medical field to save lives

Predicta Med, an Israeli startup, is developing an AI-based platform for early detection and treatment of autoimmune diseases. The company was founded in 2020 and has since partnered with institutions such as Maccabi Health Services Research Institute and US hospitals including Cedars Sinai, Mayo Clinic, and Stanford. Predicta Med has raised over $4.5 million in its previous funding round and is currently closing a Seed round with strategic investors including Cedars Sinai, Mayo Clinic, leading funds in the field, and grants from Google and the Israel Innovation Authority.

InvestmentPartners

Apr 30, 2024 · www.calcalistech.com

growth-positive

10 startups complete first cohort of SHAAR- Shaare Zedek - Arieli Healthcare innovation hub | CTech

Shaare Zedek Medical Center and investment firm Arieli Capital have launched the first cohort of their innovation hub, SHAAR. The hub, located within Shaare Zedek Medical Center, provides startups with immediate proximity to physicians, data, and medical departments. Ten startups in the Seed to A stages were selected for the first cohort, which concluded last week. The program included 440 business meetings and collaboration opportunities for clinical trials partnerships and funding opportunities. The selected companies tackled various medical concerns, such as lung cancer, brain stents, and post-surgical infections.

InvestmentPartners

Nov 16, 2022 · www.calcalistech.com

growth-positive

Sanara Ventures adds two medtech startups to tech incubator | CTech

Sanara Ventures has added two new Israeli startups, Panacea and ActiveAging, to its technology incubator. Panacea has developed a software system for optimizing clinical trials, while ActiveAging has developed an AI-based platform for managing personalized health benefits. Sanara Ventures focuses on startups in the pre-seed, Seed, and round A stages and has over 20 portfolio companies. They have also launched Sanara Capital, raising $100 million with Philips to invest in more advanced stage startups.

PartnersInvestment

Funding

Team Members

5

Employees: 1-10

Web & Social Links

Locations

Zarhin St 13, Ra'anana, Israel

Photos & Videos

No files yet

Panacea-ml Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info